Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lymphoma, Non-Hodgkin × tocilizumab × Clear all

Phase

Phase 1/2 3 Phase 1 3 Phase 2 2 Phase 3 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Arthritis, Rheumatoid 2 Stroke 1 Spondylitis, Ankylosing 1 Pulmonary Disease, Chronic Obstructive 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma 1 Kidney Failure, Chronic 1 Diabetes Mellitus 1 Coronary Artery Disease 1 COVID-19 1

Interventions

Rituximab 53 Cyclophosphamide 32 Vincristine 24 Doxorubicin 22 Prednisone 20 Bendamustine Hydrochloride 16 Etoposide 13 Radiotherapy 11 Cytarabine 9 ibrutinib 6 fludarabine 6 VAP-cyclo protocol 6 Prednisolone 6 Peripheral Blood Stem Cell Transplantation 6 Granulocyte Colony-Stimulating Factor 6 Gemcitabine 6 Filgrastim 6 pirtobrutinib 5 ibritumomab tiuxetan 5 Methotrexate 5 Melphalan 5 Lenalidomide 5 pixantrone 4 Mitoxantrone 4 Epoetin Alfa 4 Cyclosporine 4 Carmustine 4 Bleomycin 4 venetoclax 3 tositumomab I-131 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05171647 2026-03-06

SUNMO

Hoffmann-La Roche

Phase 3 Active not recruiting

208 enrolled 12 charts

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡